Patient characteristics
| . | Letermovir (n = 105), n (%) . | No letermovir (n = 105), n (%) . | P . |
|---|---|---|---|
| Patient age, median (IQR) | 60 (47-66) | 55 (45-64) | .14 |
| Patient gender, male | 68 (65) | 69 (66) | .885 |
| Disease | .717 | ||
| AML | 60 (57) | 58 (55) | |
| ALL | 8 (7.5) | 13 (12.5) | |
| MDS or MPN | 26 (25) | 24 (23) | |
| Myeloma or lymphoma | 11 (10.5) | 10 (9.5) | |
| Disease status | .381 | ||
| CR1 | 46 (44) | 38 (36) | |
| CR > 1 | 13 (12) | 19 (18) | |
| Active disease | 46 (44) | 48 (46) | |
| DRI | .363 | ||
| Low | 7 (7) | 5 (5) | |
| Intermediate | 59 (56) | 70 (66.5) | |
| High | 32 (30) | 22 (21) | |
| Very high | 7 (7) | 8 (7.5) | |
| Donor | .525 | ||
| CBU | 10 (9.5) | 14 (13) | |
| MMRD | 19 (18) | 24 (23) | |
| MMUD | 18 (17) | 19 (18) | |
| MUD | 47 (45) | 35 (33.5) | |
| MRD | 11 (10.5) | 13 (12.5) | |
| H/D CMV serostatus | .269 | ||
| Pos/neg | 54 (51) | 46 (44) | |
| Pos/pos | 51 (49) | 59 (56) | |
| Stem cell source | .39 | ||
| PB | 95 (90.5) | 91 (87) | |
| CBU | 10 (9.5) | 14 (13) | |
| GVHD prophylaxis | .06 | ||
| PTCy-sirolimus-MMF | 80 (76) | 79 (75) | |
| PTCy-sirolimus | 11 (10) | 14 (13) | |
| Sirolimus-MMF | 8 (8) | 12 (12) | |
| Other sirolimus-based | 6 (6) | 0 |
| . | Letermovir (n = 105), n (%) . | No letermovir (n = 105), n (%) . | P . |
|---|---|---|---|
| Patient age, median (IQR) | 60 (47-66) | 55 (45-64) | .14 |
| Patient gender, male | 68 (65) | 69 (66) | .885 |
| Disease | .717 | ||
| AML | 60 (57) | 58 (55) | |
| ALL | 8 (7.5) | 13 (12.5) | |
| MDS or MPN | 26 (25) | 24 (23) | |
| Myeloma or lymphoma | 11 (10.5) | 10 (9.5) | |
| Disease status | .381 | ||
| CR1 | 46 (44) | 38 (36) | |
| CR > 1 | 13 (12) | 19 (18) | |
| Active disease | 46 (44) | 48 (46) | |
| DRI | .363 | ||
| Low | 7 (7) | 5 (5) | |
| Intermediate | 59 (56) | 70 (66.5) | |
| High | 32 (30) | 22 (21) | |
| Very high | 7 (7) | 8 (7.5) | |
| Donor | .525 | ||
| CBU | 10 (9.5) | 14 (13) | |
| MMRD | 19 (18) | 24 (23) | |
| MMUD | 18 (17) | 19 (18) | |
| MUD | 47 (45) | 35 (33.5) | |
| MRD | 11 (10.5) | 13 (12.5) | |
| H/D CMV serostatus | .269 | ||
| Pos/neg | 54 (51) | 46 (44) | |
| Pos/pos | 51 (49) | 59 (56) | |
| Stem cell source | .39 | ||
| PB | 95 (90.5) | 91 (87) | |
| CBU | 10 (9.5) | 14 (13) | |
| GVHD prophylaxis | .06 | ||
| PTCy-sirolimus-MMF | 80 (76) | 79 (75) | |
| PTCy-sirolimus | 11 (10) | 14 (13) | |
| Sirolimus-MMF | 8 (8) | 12 (12) | |
| Other sirolimus-based | 6 (6) | 0 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CBU, cord blood unit; CR, complete remission; DRI, disease risk index according to Armand et al (Blood 2014); H/D CMV serostatus, host/donor CMV serological status; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MMRD, mismatched related donor; MMUD, mismatched unrelated donor; MPN, myeloproliferative neoplasm; MRD, matched related donor; MUD, 10/10 HLA-matched unrelated donor; PB, peripheral blood.